Podcast
Author(s):
Dr Short discusses data in acute lymphoblastic leukemia that were presented at the 2023 ASCO Annual Meeting and EHA Congress.
Welcome to OncLive On Air®! I’m your host today, Caroline Seymour.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by Takeda Pharmaceuticals, we had the pleasure of speaking with Nicholas James Short, MD, an assistant professor in the Department of Leukemia and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, to discuss data in acute lymphoblastic leukemia (ALL) that were presented at the 2023 ASCO Annual Meeting and EHA Congress, including findings from the phase 3 PhALLCON trial (NCT03589326), phase 2 FELIX trial (NCT04404660), and more.
In our exclusive interview, Dr Short provided post-conference insights on the role of ponatinib (Iclusig) in ALL, its effect on minimal residual disease negativity, the potential effects of obecabtagene autoleucel on the armamentarium given its pharmacodynamic and safety profile, and research highlighting the importance of immunotherapy to the future of B-ALL management.
___
That’s all we have for today! Thank you for listening to this episode of OncLive On Air®, sponsored by Takeda Pharmaceuticals. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air®.
*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer
2 Commerce Drive
Cranbury, NJ 08512